Anti-Hu CD7 PE-DyLight™ 594

*Weijler L, Kowarsch F, Wödlinger M, Reiter M, Maurer-Granofszky M, Schumich A, Dworzak MN: UMAP based anomaly detection for minimal residual disease quantification within acute myeloid leukemia. Cancers (Basel) 2022 Feb 11;14 (4) :898., URL: https://pubmed.ncbi.nlm.nih.gov/35205645/

*Nishimura M, Takanashi M, Okazaki H, Satake M, Nakajima K: Role of CD7 expressed in lung microvascular endothelial cells as Fc receptor for immunoglobulin M. Endothelium. 2006 Jul-Aug;13 (4) :287-92., URL: https://pubmed.ncbi.nlm.nih.gov/16990185/, *Chang H, Yeung J, Brandwein J, Yi QL: CD7 expression predicts poor disease free survival and post-remission survival in patients with acute myeloid leukemia and normal karyotype. Leuk Res. 2007 Feb;31 (2) :157-62. Epub 2006 Jul 11., URL: https://pubmed.ncbi.nlm.nih.gov/16837044/, *Lam GK, Liao HX, Xue Y, Alam SM, Scearce RM, Kaufman RE, Sempowski GD, Haynes BF. Expression of the CD7 ligand K-12 in human thymic epithelial cells: regulation by IFN-gamma. J Clin Immunol. 2005 Jan;25 (1) :41-9., URL: https://pubmed.ncbi.nlm.nih.gov/15742156/, *Alaibac M, Pigozzi B, Belloni-Fortina A, Michelotto A, Saponeri A, Peserico A. CD7 expression in reactive and malignant human skin T-lymphocytes. Anticancer Res. 2003 May-Jun;23 (3B) :2707-10., URL: https://pubmed.ncbi.nlm.nih.gov/12894562/